18.04
4.28%
0.74
시간 외 거래:
17.31
-0.73
-4.05%
전일 마감가:
$17.30
열려 있는:
$18.54
하루 거래량:
554.69K
Relative Volume:
1.36
시가총액:
$2.09B
수익:
$7.50M
순이익/손실:
$-81.89M
주가수익비율:
0.3403
EPS:
53.0176
순현금흐름:
$-63.58M
1주 성능:
+6.24%
1개월 성능:
+23.31%
6개월 성능:
+149.52%
1년 성능:
+839.58%
Mesoblast Ltd Adr Stock (MESO) Company Profile
MESO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
18.04 | 2.09B | 7.50M | -81.89M | -63.58M | 53.02 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-12-23 | 다운그레이드 | Jefferies | Buy → Hold |
2024-09-24 | 업그레이드 | Maxim Group | Hold → Buy |
2024-08-29 | 업그레이드 | Jefferies | Hold → Buy |
2024-07-23 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2023-08-31 | 업그레이드 | Jefferies | Hold → Buy |
2023-08-07 | 다운그레이드 | Maxim Group | Buy → Hold |
2023-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2023-08-04 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
2023-03-09 | 개시 | William Blair | Outperform |
2022-12-06 | 다운그레이드 | Jefferies | Buy → Hold |
2022-09-06 | 개시 | Piper Sandler | Overweight |
2021-04-07 | 업그레이드 | Maxim Group | Hold → Buy |
2020-12-22 | 다운그레이드 | Maxim Group | Buy → Hold |
2020-12-04 | 다운그레이드 | Chardan Capital Markets | Neutral → Sell |
2020-10-22 | 개시 | RBC Capital Mkts | Sector Perform |
2020-08-14 | 재확인 | Maxim Group | Buy |
2020-05-28 | 재확인 | H.C. Wainwright | Buy |
2019-01-31 | 재개 | H.C. Wainwright | Buy |
2018-03-22 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
2018-02-28 | 재확인 | Cantor Fitzgerald | Buy |
2017-08-31 | 개시 | Oppenheimer | Outperform |
2017-06-08 | 개시 | Cantor Fitzgerald | Buy |
모두보기
Mesoblast Ltd Adr 주식(MESO)의 최신 뉴스
MESO Stock Surges 80% In A Month After FDA Approval Of GVHD Drug - Barchart
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Investors: What’s The Real Deal With W & T Offshore Inc (NYSE: WTI) - Stocks Register
What Analysts Think About TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP)’s Potential Raise - Stocks Register
No Stopping Argo Blockchain Plc ADR (NASDAQ: ARBK)’s Stock Plunged? - Stocks Register
NIO Inc ADR (NYSE: NIO) Stock Forecast: Could Pass $8 In A Year - Stocks Register
If You Don’t Buy Safe Pro Group Inc (NASDAQ: SPAI) Now, You’ll Regret It Later - Stocks Register
What Do Analysts Think About Aspen Aerogels Inc’s (NYSE:ASPN) Future? - Stocks Register
Would I Buy Opendoor Technologies Inc (NASDAQ: OPEN) Stock At Any Time In The Future? - Stocks Register
Tempest Therapeutics Inc (NASDAQ: TPST) Investors Should Be Worried About This. - Stocks Register
Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday - Benzinga
Petco Health and Wellness Co Inc (NASDAQ: WOOF): A Hidden Gem Despite Volatility - Stocks Register
Where Do Analysts See Gamestop Corporation (NYSE: GME) Heading? - Stocks Register
Mesoblast Stock Soars to 52-Week High, Hits $19.15 - Investing.com
Here’s Why Lineage Cell Therapeutics Inc (AMEX: LCTX) Is An Attractive Investment Right Now - Stocks Register
No Stopping Editas Medicine Inc (NASDAQ: EDIT)’s Stock Plunged? - Stocks Register
What Do Analysts Think About Therealreal Inc’s (NASDAQ:REAL) Future? - Stocks Register
What Awaits These 4 Biotech Stocks That More Than Doubled In 2024 - Barchart
Mesoblast share price rockets 30% on big US FDA news - The Motley Fool Australia
Mesoblast stock soars to 52-week high, hits $12.21 - Investing.com
Stem Cell Banking Market to Surpass Value of USD 18.65 Billion By 2031 | SkyQuest Technology - Benzinga
Mesoblast Stock Soars to 52-Week High, Hits $12.19 - Investing.com
Best Momentum Stocks to Buy for November 26th - Yahoo Finance
Investors Heavily Search Sea Limited Sponsored ADR (SE): Here is What You Need to Know - Yahoo Finance
Mesoblast stock soars to 52-week high, hits $11.1 - Investing.com
Mesoblast files annual report and meeting notice - Investing.com India
JPMorgan Takes Substantial Stake in Mesoblast Ltd - TipRanks
Mesoblast stock soars to 52-week high, hits $8.7 - Investing.com
What Makes Holcim Ltd Unsponsored ADR (HCMLY) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Mesoblast stock gains momentum ahead of 2025 PDUFA dateJefferies - Investing.com
The Psychology of Mesoblast Ltd ADR Inc. (MESO) Price Performance: Understanding Market Sentiment - The InvestChronicle
Why Argosy Minerals, Flight Centre, Mesoblast, and Telix shares are sinking today - The Motley Fool
Australia stocks higher at close of trade; S&P/ASX 200 up 0.50% - Investing.com
Mesoblast: Rolling The Dice On Cellular Medicines (NASDAQ:MESO) - Seeking Alpha
Australia stocks higher at close of trade; S&P/ASX 200 up 0.81% - Investing.com
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
Mesoblast Limited: Back From The Dead (NASDAQ:MESO) - Seeking Alpha
Australia stocks higher at close of trade; S&P/ASX 200 up 0.99% - Investing.com
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Benzinga
11 Best ASX Stocks To Buy Now - Yahoo Finance
Sea Limited (SE) to Report Q4 Earnings: What's in Store? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
10 Best Australian Stocks To Buy - Yahoo Finance
Mesoblast Ltd receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
Top Penny Stocks for Q3 2023 - Investopedia
Here’s why Mesoblast shares are in a trading halt today - The Motley Fool Australia
Class action proposed against biotech Mesoblast after historic collapse in share price - Business News Australia
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares - Yahoo Finance
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
Exclusive Interview With Pluristem Therapeutics Inc.(NASDAQ:PSTI) President Yaky Yanay - Market Exclusive
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) On Track to Becoming Largest Generics Manufacturer - The Wall Street Transcript
Mesoblast Ltd Adr (MESO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):